This Just Makes Me Sick!

Recs

3

Be A Motley Fool Millionaire!

David Gardner's top pick took an epic run of 1,334%! See what he’s recommending that you buy NEXT.

GlaxoSmithKline's (NYSE: GSK) press release yesterday was enough to make me nauseous. Seriously. Unfortunately, I won't be able to take the British company's anti-nausea medication, Rezonic, because the marketing approval was turned down by the Food and Drug Administration.

It wasn't the rejection that had me nauseous, but the information in the press release. Or lack thereof. At just four sentences -- excluding disclosures -- it didn't let investors know anything about the chances of approval for Rezonic.

Johnson & Johnson (NYSE: JNJ) is equally famous for terse press releases when the company gets complete response letters. The part of the press release about the FDA's decision to reject Risperdal Consta for bipolar disorder was also just four sentences, but at least it let investors know that no additional trials were needed.

Companies will argue that they need to keep the "complete response letter" from the FDA a secret for competitive reasons. That may be so, but how about at least throwing investors a bone so they can get a feel for how long the wait might be?

The worst part is that investors have already been waiting for a while for a decision by the FDA on Rezonic. The original PDUFA date was at the end of March. As I wrote at the time, the data looked good, but we don't have any way of knowing what kind of additional information the FDA wants before it'll approve the drug.

Rezonic will be prescribed with Glaxo's current treatment, Zofran, to prevent nausea and vomiting after chemotherapy or surgery. Zofran is only a $200 million-a-year drug, but since adding Rezonic increases the effectiveness, Glaxo might be able to take some market share from Merck's (NYSE: MRK) Emend, Eisai's Aloxi, and Solvay Pharmaceuticals' Marinol, which is available as a generic from Par Pharmaceutical (NYSE: PRX). That is, if the FDA actually approves the drug ... someday.

There are no secrets in Fooldom:

“Make Big Money With Options” Motley Fool CFO Ollen Douglass recently made over $100,000 buying options on 7 well known stocks. Now we’re committed to turning his small fortune into a massive one! And we want you to join us! Enter your email address to hear more:

International investing could be the next big growth area. To read more about why this could be so, take a free 30-day trial to Motley Fool Global Gains, today. 

Fool contributor Brian Orelli, Ph.D., doesn't own shares of any company mentioned in this article. Johnson & Johnson is an Income Investor selection. The Fool has a disclosure policy.

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On June 29, 2009, at 3:44 AM, MyDonkey wrote:

    I think you mean "nauseated" [verb], not "nauseous" [adjective] -- as in: "The nauseous smell made me nauseated."

    A nauseous person is a sickening person (liable to make other people sick), and if I went on and on about this for several paragraphs, I would probably become nauseous to a few readers.

Add your comment.

Compare Brokers

TD AMERITRADE
more info
ShareBuilder
more info
Power E*Trade

more info
Scottrade
more info
Fool Disclosure

DocumentId: 928045, ~/Articles/ArticleHandler.aspx, 12/3/2009 9:21:14 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

The Must-Read Story on Fool.com
Fool Search: Be GM's Next CEO!

By The Motley Fool

Fool Search: Be GM's Next CEO!

Related Tickers

12/2/2009 4:02 PM
GSK $42.38 Down -0.03 -0.07%
GlaxoSmithKline pl… CAPS Rating: *****
JNJ $63.88 Up +0.37 +0.58%
Johnson & Johnson CAPS Rating: *****
MRK $36.80 Down -0.08 -0.22%
Merck & Co., Inc. CAPS Rating: ****
PRX $24.47 Up +0.05 +0.20%
Par Pharmaceutical… CAPS Rating: **

Community: Investing Wiki

Term Of The Hour

Fund manager: A fund manager is the controlling authority of an individual mutual fund. The fund manager is hired by the board of directors who in turn are elected by the shareholders in the fund.

Want to learn more or edit this definition?
Click here to read more!